Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. [electronic resource]
Producer: 20151120Description: 747-57 p. digitalISSN:- 1744-8301
- Administration, Oral
- Animals
- Antineoplastic Agents -- chemistry
- Clinical Trials as Topic
- Drug Evaluation, Preclinical
- Female
- Humans
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors -- chemistry
- Poly(ADP-ribose) Polymerases -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.